دورية أكاديمية
TP53 to mediate immune escape in tumor microenvironment: an overview of the research progress.
| العنوان: | TP53 to mediate immune escape in tumor microenvironment: an overview of the research progress. |
|---|---|
| المؤلفون: | Zhu KL; The First Clinical Medical College of Lanzhou University, Lanzhou, 730000, Gansu, People's Republic of China., Su F; The First Clinical Medical College of Lanzhou University, Lanzhou, 730000, Gansu, People's Republic of China.; Department of Oncology, The First Hospital of Lanzhou University, Lanzhou, 730000, Gansu, People's Republic of China., Yang JR; The First Clinical Medical College of Lanzhou University, Lanzhou, 730000, Gansu, People's Republic of China.; Department of Oncology, The First Hospital of Lanzhou University, Lanzhou, 730000, Gansu, People's Republic of China., Xiao RW; Department of Oncology, The First Hospital of Lanzhou University, Lanzhou, 730000, Gansu, People's Republic of China., Wu RY; The First Clinical Medical College of Lanzhou University, Lanzhou, 730000, Gansu, People's Republic of China., Cao MY; The First Clinical Medical College of Lanzhou University, Lanzhou, 730000, Gansu, People's Republic of China., Ling XL; The First Clinical Medical College of Lanzhou University, Lanzhou, 730000, Gansu, People's Republic of China. ldyy_lingxl@lzu.edu.cn.; Department of Oncology, The First Hospital of Lanzhou University, Lanzhou, 730000, Gansu, People's Republic of China. ldyy_lingxl@lzu.edu.cn., Zhang T; The First Clinical Medical College of Lanzhou University, Lanzhou, 730000, Gansu, People's Republic of China. zhangt18@lzu.edu.cn.; Department of Oncology, The First Hospital of Lanzhou University, Lanzhou, 730000, Gansu, People's Republic of China. zhangt18@lzu.edu.cn. |
| المصدر: | Molecular biology reports [Mol Biol Rep] 2024 Jan 25; Vol. 51 (1), pp. 205. Date of Electronic Publication: 2024 Jan 25. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Reidel Country of Publication: Netherlands NLM ID: 0403234 Publication Model: Electronic Cited Medium: Internet ISSN: 1573-4978 (Electronic) Linking ISSN: 03014851 NLM ISO Abbreviation: Mol Biol Rep Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Dordrecht, Boston, Reidel. |
| مواضيع طبية MeSH: | Tumor Suppressor Protein p53*/genetics , Neoplasms*/genetics, Humans ; Genes, p53 ; Cognition ; Genomic Instability ; Tumor Microenvironment/genetics |
| مستخلص: | Increasing evidence suggests that key cancer-causing driver genes continue to exert a sustained influence on the tumor microenvironment (TME), highlighting the importance of immunotherapeutic targeting of gene mutations in governing tumor progression. TP53 is a prominent tumor suppressor that encodes the p53 protein, which controls the initiation and progression of different tumor types. Wild-type p53 maintains cell homeostasis and genomic instability through complex pathways, and mutant p53 (Mut p53) promotes tumor occurrence and development by regulating the TME. To date, it has been wildly considered that TP53 is able to mediate tumor immune escape. Herein, we summarized the relationship between TP53 gene and tumors, discussed the mechanism of Mut p53 mediated tumor immune escape, and summarized the progress of applying p53 protein in immunotherapy. This study will provide a basic basis for further exploration of therapeutic strategies targeting p53 protein. (© 2024. The Author(s).) |
| References: | Science. 2022 Apr 29;376(6592):eabi8175. (PMID: 35482859) Clin Cancer Res. 2006 Aug 1;12(15):4523-32. (PMID: 16899598) Biochem Pharmacol. 2002 Apr 1;63(7):1219-28. (PMID: 11960598) Cancers (Basel). 2023 Mar 02;15(5):. (PMID: 36900354) Front Immunol. 2020 Aug 04;11:1731. (PMID: 32849616) Chem Biol Drug Des. 2019 May;93(5):760-786. (PMID: 30697932) Clin Cancer Res. 2017 Jun 15;23(12):3012-3024. (PMID: 28039262) Cancer Lett. 2016 Jul 1;376(2):303-9. (PMID: 27045472) Cancer Lett. 2018 Mar 1;416:124-137. (PMID: 29274359) Trends Cancer. 2021 Jun;7(6):525-540. (PMID: 33358111) Cell. 2017 Nov 2;171(4):934-949.e16. (PMID: 29033130) Int J Mol Sci. 2021 Jun 29;22(13):. (PMID: 34209703) Oncogene. 2018 Sep;37(39):5257-5268. (PMID: 29855617) Nat Commun. 2013;4:2359. (PMID: 23965983) Nat Commun. 2018 Feb 22;9(1):771. (PMID: 29472616) Front Oncol. 2021 Jun 11;11:642603. (PMID: 34178628) Clin Cancer Res. 2018 Mar 15;24(6):1315-1325. (PMID: 29301826) Cancer Cell. 2012 Sep 11;22(3):291-303. (PMID: 22975373) Cell Death Dis. 2016 Jan 21;7:e2015. (PMID: 26775693) Invest New Drugs. 2018 Aug;36(4):629-637. (PMID: 29196957) J Clin Oncol. 2022 Feb 1;40(4):369-381. (PMID: 34860572) J Immunother Cancer. 2022 May;10(5):. (PMID: 35606086) Theranostics. 2018 Jan 1;8(1):61-77. (PMID: 29290793) Cell Death Differ. 2018 Mar;25(3):460-470. (PMID: 29238070) Front Immunol. 2020 Dec 03;11:583084. (PMID: 33365025) Mol Cell. 2014 Dec 4;56(5):617-29. (PMID: 25454946) Bioessays. 2020 Oct;42(10):e1900221. (PMID: 32363691) J Mol Cell Biol. 2019 Apr 1;11(4):293-305. (PMID: 30508182) Biochim Biophys Acta. 2015 Jan;1853(1):89-100. (PMID: 25311384) Cell Immunol. 2022 Jan;371:104458. (PMID: 34847407) Front Oncol. 2023 Jan 11;12:1094210. (PMID: 36713582) Blood. 2020 Dec 10;136(24):2812-2823. (PMID: 32730593) Biosci Biotechnol Biochem. 2020 Feb;84(2):256-267. (PMID: 31601153) Trends Biochem Sci. 2016 Mar;41(3):211-218. (PMID: 26778478) Sci Transl Med. 2019 Dec 18;11(523):. (PMID: 31852795) CNS Oncol. 2022 Jun 1;11(2):CNS87. (PMID: 35575067) Medicina (Kaunas). 2019 Dec 30;56(1):. (PMID: 31906017) Front Mol Biosci. 2023 Aug 01;10:1148389. (PMID: 37602328) J Cell Physiol. 2019 Jun;234(6):8509-8521. (PMID: 30520029) Nat Rev Clin Oncol. 2019 Mar;16(3):151-167. (PMID: 30523282) Cancer Res. 2010 Dec 1;70(23):9650-8. (PMID: 20952507) Front Endocrinol (Lausanne). 2019 Mar 12;10:152. (PMID: 30915036) Curr Pharm Des. 2018;24(30):3566-3575. (PMID: 30255744) Cancer Lett. 2020 Feb 1;470:126-133. (PMID: 31730903) Front Cell Dev Biol. 2021 Oct 18;9:762651. (PMID: 34733856) Front Oncol. 2020 Nov 06;10:595187. (PMID: 33240819) Front Immunol. 2021 Aug 13;12:707734. (PMID: 34484205) Cell Metab. 2023 Sep 5;35(9):1580-1596.e9. (PMID: 37506695) Int J Mol Sci. 2018 Oct 24;19(11):. (PMID: 30355984) Blood. 2018 Jan 4;131(1):39-48. (PMID: 29118006) J Hematol Oncol. 2022 Nov 1;15(1):160. (PMID: 36319992) Cell Mol Life Sci. 2021 Mar;78(5):1853-1860. (PMID: 33070220) Lancet. 2023 Jul 8;402(10396):142-158. (PMID: 37271153) IET Nanobiotechnol. 2023 May;17(3):246-256. (PMID: 36727937) Int J Oncol. 2013 Dec;43(6):1817-23. (PMID: 24064862) Cancer Res. 2021 Jun 1;81(11):3079-3091. (PMID: 33504557) Cell Death Dis. 2022 Nov 18;13(11):974. (PMID: 36400749) Int J Mol Sci. 2017 Dec 19;18(12):. (PMID: 29257071) Exp Cell Res. 2022 Aug 1;417(1):113210. (PMID: 35597298) Physiol Rev. 2021 Jan 1;101(1):147-176. (PMID: 32466724) Front Oncol. 2015 Dec 21;5:289. (PMID: 26734571) Oncol Lett. 2018 Sep;16(3):2851-2856. (PMID: 30127871) Science. 2021 Mar 5;371(6533):. (PMID: 33649166) Mol Metab. 2020 Mar;33:83-101. (PMID: 31668988) Life Sci. 2023 Feb 15;315:121361. (PMID: 36608871) Arch Biochem Biophys. 2020 Jan 15;679:108219. (PMID: 31812668) Nature. 2019 May;569(7755):270-274. (PMID: 31043744) Crit Rev Immunol. 2015;35(6):433-49. (PMID: 27279042) Mol Aspects Med. 2021 Aug;80:100870. (PMID: 32800530) J Immunol. 2021 Mar 15;206(6):1395-1404. (PMID: 33547170) J Mol Cell Biol. 2019 Jul 19;11(7):600-604. (PMID: 31318969) Oncogene. 2019 Jan;38(4):533-548. (PMID: 30158673) J Immunol. 2015 Jan 1;194(1):418-28. (PMID: 25404359) Cells. 2022 Jul 09;11(14):. (PMID: 35883598) Nat Commun. 2013;4:2935. (PMID: 24343302) Bioact Mater. 2023 Oct 14;32:277-291. (PMID: 37876556) Nat Rev Endocrinol. 2016 Jan;12(1):15-28. (PMID: 26553134) Sci China Life Sci. 2023 Jan;66(1):94-109. (PMID: 35982377) Front Immunol. 2020 Jan 21;10:3038. (PMID: 32038612) Nat Commun. 2022 Feb 9;13(1):758. (PMID: 35140208) ACS Nano. 2014 Jun 24;8(6):5494-514. (PMID: 24811110) Oncotarget. 2019 Mar 15;10(22):2151-2160. (PMID: 31040907) Am J Cancer Res. 2020 Mar 01;10(3):727-742. (PMID: 32266087) Onco Targets Ther. 2020 Feb 14;13:1355-1363. (PMID: 32104002) Genome Biol. 2022 Oct 17;23(1):218. (PMID: 36253792) Cancer Commun (Lond). 2023 Jan;43(1):3-41. (PMID: 36424360) J Hematol Oncol. 2019 Aug 22;12(1):84. (PMID: 31438991) Cancer Discov. 2021 Dec 1;11(12):3090-3105. (PMID: 34230007) Clin Cancer Res. 2001 May;7(5):1398-409. (PMID: 11350911) EMBO Rep. 2016 Feb;17(2):188-201. (PMID: 26691213) Cell Cycle. 2020 Jun;19(11):1338-1351. (PMID: 32275841) Cell Mol Gastroenterol Hepatol. 2020;10(2):391-418. (PMID: 32304779) Pharmaceutics. 2021 Dec 03;13(12):. (PMID: 34959348) Nature. 2019 Aug;572(7770):538-542. (PMID: 31367040) J Cell Sci. 2020 Mar 6;133(5):. (PMID: 32144194) Nat Biotechnol. 2022 Aug;40(8):1190-1199. (PMID: 35314812) Cancer Cell. 2021 Apr 12;39(4):494-508.e5. (PMID: 33545063) Nature. 2016 May 18;533(7604):493-498. (PMID: 27225120) Cancers (Basel). 2021 Jul 03;13(13):. (PMID: 34283062) J Mol Cell Biol. 2020 Sep 1;12(9):674-687. (PMID: 32722796) J Transl Med. 2021 Jun 17;19(1):264. (PMID: 34140005) Nat Rev Immunol. 2018 Aug;18(8):527-535. (PMID: 29662120) Cell Death Differ. 2019 Jan;26(2):199-212. (PMID: 30538286) Front Immunol. 2023 Aug 24;14:1212476. (PMID: 37691932) Mol Cancer. 2019 Feb 27;18(1):29. (PMID: 30813924) Brief Bioinform. 2021 Nov 5;22(6):. (PMID: 34329375) EBioMedicine. 2019 Apr;42:431-442. (PMID: 30935888) Int J Mol Sci. 2016 Nov 19;17(11):. (PMID: 27869779) Int J Mol Sci. 2020 May 13;21(10):. (PMID: 32414156) Expert Opin Ther Targets. 2018 Apr;22(4):343-351. (PMID: 29468927) Int J Mol Sci. 2022 Apr 30;23(9):. (PMID: 35563397) Cancer Gene Ther. 2012 Aug;19(8):530-7. (PMID: 22595792) |
| معلومات مُعتمدة: | 81802269 Tao Zhang; 82260518 Tao Zhang; 21JR7RA390 Tao Zhang; 22YF7FA086 Tao Zhang; lzuyxcx-2022-183,2020-ZD-74 Tao Zhang; 2022LQTD24 Tao Zhang; cphcf-2022-013 Xiao-ling Ling; 21JR11R076 Xiao-ling Ling; 2021SHFZ006 Xiao-ling Ling |
| فهرسة مساهمة: | Keywords: Immune escape; Immunotherapy; TP53; Tumors |
| المشرفين على المادة: | 0 (Tumor Suppressor Protein p53) 0 (TP53 protein, human) |
| تواريخ الأحداث: | Date Created: 20240125 Date Completed: 20240126 Latest Revision: 20240128 |
| رمز التحديث: | 20240128 |
| مُعرف محوري في PubMed: | PMC10811008 |
| DOI: | 10.1007/s11033-023-09097-7 |
| PMID: | 38270700 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1573-4978 |
|---|---|
| DOI: | 10.1007/s11033-023-09097-7 |